Selected research
Market Structure
Global Exosome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Exosome CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Exosome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Exosome CDMO include REPROCELL, Histocell, Lonza, MYCENAX, RoosterBio, Altaris LLC, Asahi Glass Co., Fortis Life Sciences and Scorpius BioManufacturing, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Exosome CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Exosome CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Exosome CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Exosome CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.
Exosome CDMO Segment by Company
REPROCELL
Histocell
Lonza
MYCENAX
RoosterBio
Altaris LLC
Asahi Glass Co.
Fortis Life Sciences
Scorpius BioManufacturing
Miltenyi Bioindustry
Exothera
EXO Biologics
Porton Advanced
Elise Biopharma
Evox Therapeutics
FUJIFILM Biotechnologies
Exosome CDMO Segment by Type
Preclinical CRO
Clinical CRO
Exosome CDMO Segment by Application
Laboratory
Universities
Bio Industry
Medical Industry
Exosome CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Exosome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Exosome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Exosome CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Exosome CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Exosome CDMO industry.
Chapter 3: Detailed analysis of Exosome CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Exosome CDMOrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Preclinical CRO
- Clinical CRO
Applications
- Laboratory
- Universities
- Bio Industry
- Medical Industry
Companies covered
- REPROCELL
- Histocell
- Lonza
- MYCENAX
- RoosterBio
- Altaris LLC
- Asahi Glass Co.
- Fortis Life Sciences
- Scorpius BioManufacturing
- Miltenyi Bioindustry
- Exothera
- EXO Biologics
- Porton Advanced
- Elise Biopharma
- Evox Therapeutics
- FUJIFILM Biotechnologies
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Exosome CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Preclinical CRO
- 1.2.3 Clinical CRO
- 1.3 Market Analysis by Application
- 1.3.1 Global Exosome CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Laboratory
- 1.3.3 Universities
- 1.3.4 Bio Industry
- 1.3.5 Medical Industry
- 1.4 Global Market Growth Prospects
- 1.5 Global Exosome CDMO Growth Trends by Region
- 1.5.1 Global Exosome CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Exosome CDMO Market Size by Region (2021-2026)
- 1.5.3 Exosome CDMO Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Exosome CDMO Market Dynamics
- 2.1 Exosome CDMO Industry Trends
- 2.2 Exosome CDMO Industry Drivers
- 2.3 Exosome CDMO Industry Opportunities and Challenges
- 2.4 Exosome CDMO Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Exosome CDMO Revenue by Company (2021-2026)
- 3.2 Global Exosome CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Exosome CDMO Key Company Head office and Area Served
- 3.4 Global Exosome CDMO Company, Product Type & Application
- 3.5 Global Exosome CDMO Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Exosome CDMO Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Exosome CDMO Players Market Share by Revenue in 2025
- 3.6.3 2025 Exosome CDMO Tier 1, Tier 2, and Tier 3
4 Exosome CDMO Market by Type
- 4.1 Global Exosome CDMO Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Exosome CDMO Market Size by Type (2021-2032)
- 4.3 Global Exosome CDMO Market Size Share by Type (2021-2032)
5 Exosome CDMO Market by Application
- 5.1 Global Exosome CDMO Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Exosome CDMO Market Size by Application (2021-2032)
- 5.3 Global Exosome CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 REPROCELL
- 6.1.1 REPROCELL Company Information
- 6.1.2 REPROCELL Business Overview
- 6.1.3 REPROCELL Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 REPROCELL Exosome CDMO Product Portfolio
- 6.1.5 REPROCELL Recent Developments
- 6.2 Histocell
- 6.2.1 Histocell Company Information
- 6.2.2 Histocell Business Overview
- 6.2.3 Histocell Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Histocell Exosome CDMO Product Portfolio
- 6.2.5 Histocell Recent Developments
- 6.3 Lonza
- 6.3.1 Lonza Company Information
- 6.3.2 Lonza Business Overview
- 6.3.3 Lonza Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Lonza Exosome CDMO Product Portfolio
- 6.3.5 Lonza Recent Developments
- 6.4 MYCENAX
- 6.4.1 MYCENAX Company Information
- 6.4.2 MYCENAX Business Overview
- 6.4.3 MYCENAX Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 MYCENAX Exosome CDMO Product Portfolio
- 6.4.5 MYCENAX Recent Developments
- 6.5 RoosterBio
- 6.5.1 RoosterBio Company Information
- 6.5.2 RoosterBio Business Overview
- 6.5.3 RoosterBio Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 RoosterBio Exosome CDMO Product Portfolio
- 6.5.5 RoosterBio Recent Developments
- 6.6 Altaris LLC
- 6.6.1 Altaris LLC Company Information
- 6.6.2 Altaris LLC Business Overview
- 6.6.3 Altaris LLC Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Altaris LLC Exosome CDMO Product Portfolio
- 6.6.5 Altaris LLC Recent Developments
- 6.7 Asahi Glass Co.
- 6.7.1 Asahi Glass Co. Company Information
- 6.7.2 Asahi Glass Co. Business Overview
- 6.7.3 Asahi Glass Co. Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Asahi Glass Co. Exosome CDMO Product Portfolio
- 6.7.5 Asahi Glass Co. Recent Developments
- 6.8 Fortis Life Sciences
- 6.8.1 Fortis Life Sciences Company Information
- 6.8.2 Fortis Life Sciences Business Overview
- 6.8.3 Fortis Life Sciences Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Fortis Life Sciences Exosome CDMO Product Portfolio
- 6.8.5 Fortis Life Sciences Recent Developments
- 6.9 Scorpius BioManufacturing
- 6.9.1 Scorpius BioManufacturing Company Information
- 6.9.2 Scorpius BioManufacturing Business Overview
- 6.9.3 Scorpius BioManufacturing Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Scorpius BioManufacturing Exosome CDMO Product Portfolio
- 6.9.5 Scorpius BioManufacturing Recent Developments
- 6.10 Miltenyi Bioindustry
- 6.10.1 Miltenyi Bioindustry Company Information
- 6.10.2 Miltenyi Bioindustry Business Overview
- 6.10.3 Miltenyi Bioindustry Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Miltenyi Bioindustry Exosome CDMO Product Portfolio
- 6.10.5 Miltenyi Bioindustry Recent Developments
- 6.11 Exothera
- 6.11.1 Exothera Company Information
- 6.11.2 Exothera Business Overview
- 6.11.3 Exothera Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Exothera Exosome CDMO Product Portfolio
- 6.11.5 Exothera Recent Developments
- 6.12 EXO Biologics
- 6.12.1 EXO Biologics Company Information
- 6.12.2 EXO Biologics Business Overview
- 6.12.3 EXO Biologics Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 EXO Biologics Exosome CDMO Product Portfolio
- 6.12.5 EXO Biologics Recent Developments
- 6.13 Porton Advanced
- 6.13.1 Porton Advanced Company Information
- 6.13.2 Porton Advanced Business Overview
- 6.13.3 Porton Advanced Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Porton Advanced Exosome CDMO Product Portfolio
- 6.13.5 Porton Advanced Recent Developments
- 6.14 Elise Biopharma
- 6.14.1 Elise Biopharma Company Information
- 6.14.2 Elise Biopharma Business Overview
- 6.14.3 Elise Biopharma Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Elise Biopharma Exosome CDMO Product Portfolio
- 6.14.5 Elise Biopharma Recent Developments
- 6.15 Evox Therapeutics
- 6.15.1 Evox Therapeutics Company Information
- 6.15.2 Evox Therapeutics Business Overview
- 6.15.3 Evox Therapeutics Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Evox Therapeutics Exosome CDMO Product Portfolio
- 6.15.5 Evox Therapeutics Recent Developments
- 6.16 FUJIFILM Biotechnologies
- 6.16.1 FUJIFILM Biotechnologies Company Information
- 6.16.2 FUJIFILM Biotechnologies Business Overview
- 6.16.3 FUJIFILM Biotechnologies Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 FUJIFILM Biotechnologies Exosome CDMO Product Portfolio
- 6.16.5 FUJIFILM Biotechnologies Recent Developments
7 North America
- 7.1 North America Exosome CDMO Market Size (2021-2032)
- 7.2 North America Exosome CDMO Market Size by Type
- 7.2.1 North America Exosome CDMO Market Size by Type (2021-2026)
- 7.2.2 North America Exosome CDMO Market Size by Type (2027-2032)
- 7.2.3 North America Exosome CDMO Market Share by Type (2021-2032)
- 7.3 North America Exosome CDMO Market Size by Application
- 7.3.1 North America Exosome CDMO Market Size by Application (2021-2026)
- 7.3.2 North America Exosome CDMO Market Size by Application (2027-2032)
- 7.3.3 North America Exosome CDMO Market Share by Application (2021-2032)
- 7.4 North America Exosome CDMO Market Size by Country
- 7.4.1 North America Exosome CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Exosome CDMO Market Size by Country (2021-2026)
- 7.4.3 North America Exosome CDMO Market Size by Country (2027-2032)
- 7.4.4 North America Exosome CDMO Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Exosome CDMO Market Size (2021-2032)
- 8.2 Europe Exosome CDMO Market Size by Type
- 8.2.1 Europe Exosome CDMO Market Size by Type (2021-2026)
- 8.2.2 Europe Exosome CDMO Market Size by Type (2027-2032)
- 8.2.3 Europe Exosome CDMO Market Share by Type (2021-2032)
- 8.3 Europe Exosome CDMO Market Size by Application
- 8.3.1 Europe Exosome CDMO Market Size by Application (2021-2026)
- 8.3.2 Europe Exosome CDMO Market Size by Application (2027-2032)
- 8.3.3 Europe Exosome CDMO Market Share by Application (2021-2032)
- 8.4 Europe Exosome CDMO Market Size by Country
- 8.4.1 Europe Exosome CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Exosome CDMO Market Size by Country (2021-2026)
- 8.4.3 Europe Exosome CDMO Market Size by Country (2027-2032)
- 8.4.4 Europe Exosome CDMO Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Exosome CDMO Market Size (2021-2032)
- 9.2 China Exosome CDMO Market Size by Type
- 9.2.1 China Exosome CDMO Market Size by Type (2021-2026)
- 9.2.2 China Exosome CDMO Market Size by Type (2027-2032)
- 9.2.3 China Exosome CDMO Market Share by Type (2021-2032)
- 9.3 China Exosome CDMO Market Size by Application
- 9.3.1 China Exosome CDMO Market Size by Application (2021-2026)
- 9.3.2 China Exosome CDMO Market Size by Application (2027-2032)
- 9.3.3 China Exosome CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Exosome CDMO Market Size (2021-2032)
- 10.2 Asia Exosome CDMO Market Size by Type
- 10.2.1 Asia Exosome CDMO Market Size by Type (2021-2026)
- 10.2.2 Asia Exosome CDMO Market Size by Type (2027-2032)
- 10.2.3 Asia Exosome CDMO Market Share by Type (2021-2032)
- 10.3 Asia Exosome CDMO Market Size by Application
- 10.3.1 Asia Exosome CDMO Market Size by Application (2021-2026)
- 10.3.2 Asia Exosome CDMO Market Size by Application (2027-2032)
- 10.3.3 Asia Exosome CDMO Market Share by Application (2021-2032)
- 10.4 Asia Exosome CDMO Market Size by Country
- 10.4.1 Asia Exosome CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Exosome CDMO Market Size by Country (2021-2026)
- 10.4.3 Asia Exosome CDMO Market Size by Country (2027-2032)
- 10.4.4 Asia Exosome CDMO Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Exosome CDMO Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Exosome CDMO Market Size by Type
- 11.2.1 South America, Middle East & Africa Exosome CDMO Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Exosome CDMO Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Exosome CDMO Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Exosome CDMO Market Size by Application
- 11.3.1 South America, Middle East & Africa Exosome CDMO Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Exosome CDMO Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Exosome CDMO Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Exosome CDMO Market Size by Country
- 11.4.1 South America, Middle East & Africa Exosome CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Exosome CDMO Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Exosome CDMO Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Exosome CDMO Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst